Lonza contracted to make API for Aurinia's lupus nephritis candidate

By Gareth Macdonald

- Last updated on GMT


Related tags Pharmaceutical drug Pharmacology

Lonza has been contracted to the API for a candidate lupus nephritis treatment by Canadian developer Aurinia Pharmaceuticals Inc. 

The deal – financial terms of which were not disclosed – will see Lonza make supplies of the active pharmaceutical ingredient (API) voclosporin for a Phase III trial​ that is due to start in the first half of 2017.

The contract includes an option that would see Lonza supply the active ingredient on an exclusive basis for a period of 20 years if Aurinia wins approval for the drug.

A Lonza spokesman told us the API will be produced at the firm's facility in Visp, Switzerland.


Voclosporin is an immunosuppressant that inhibits calcineurin, an enzyme that activates T cells that is also known to play a role in damaging autoimmune diseases like lupus.

The drug was discovered by Canadian Isotechnika Pharma.

Isotechnika licensed voclosporin – then known as ISAtx247 - to Roche in 2002​ in deal focused on developing the drug for the prevention of organ rejection after a transplant.

However, the Swiss drug handed back rights to the drug a few years later citing a change in development priorities.

While the partnership did not generate any products, Roche’s involvement prompted revision of the voclosporin manufacturing process​ to ensure that a more bioavailable version of the API was produced.

Other licensees

Isotechnika also licensed voclosporin to Lux Biosciences GmbH. However, Lux abandoned efforts to develop it as a treatment for the eye disorder uveitis in 2011​ after being unable to demonstrate efficacy.

In 2013, Isotechnika merged with Vifor spin-out firm Aurinia to focus on developing voclosporin for nephrology indications.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more